{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T14:23:00Z","timestamp":1771078980326,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ahj.2020.12.009","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T17:38:20Z","timestamp":1608658700000},"page":"122-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic"],"prefix":"10.1016","volume":"233","author":[{"given":"Joban","family":"Vaishnav","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abby","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0728-2365","authenticated-orcid":false,"given":"Jessica E.","family":"Chasler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Lepley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Cuomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4233-9961","authenticated-orcid":false,"given":"Sarah","family":"Riley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Menzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johana","family":"Fajardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavita","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel P.","family":"Judge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart D.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisha A.","family":"Gilotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2020.12.009_bib0001","article-title":"Epidemiology of cardiac amyloidosis\u2013associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States","volume":"12","author":"Gilstrap Lauren","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.12.009_bib0002","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.amjcard.2019.08.045","article-title":"Increasing rate of hospital admissions in patients with amyloidosis (from the National Inpatient Sample)","volume":"124","author":"Sperry","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2020.12.009_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25819","article-title":"Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment","author":"Gertz","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ahj.2020.12.009_bib0004","first-page":"117","article-title":"Amyloidosis for the Cardiologist and Oncologist.","volume":"1","author":"Witteles","year":"2019","journal-title":"JACC"},{"key":"10.1016\/j.ahj.2020.12.009_bib0005","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","author":"Maurer","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahj.2020.12.009_bib0006","first-page":"1","article-title":"Intravenous Diuretic therapy for the management of heart failure and volume overload in a multidisciplinary outpatient unit","volume":"4","author":"Buckley","year":"2016","journal-title":"JACC"},{"key":"10.1016\/j.ahj.2020.12.009_bib0007","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1751-7133.2011.00224.x","article-title":"Open access to an outpatient intravenous diuresis program in a systolic heart failure disease management program","volume":"17","author":"Hebert","year":"2011","journal-title":"Congest Heart Failure"},{"key":"10.1016\/j.ahj.2020.12.009_bib0008","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ejheart.2008.01.003","article-title":"Outpatient intravenous diuretic therapy; potential for marked reduction in hospitalisations for acute decompensated heart failure","volume":"10","author":"Ryder","year":"2008","journal-title":"Eur J Heart Failure"},{"key":"10.1016\/j.ahj.2020.12.009_bib0009","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.amjmed.2014.11.028","article-title":"The diuresis clinic: a new paradigm for the treatment of mild decompensated heart failure","volume":"128","author":"Makadia","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.ahj.2020.12.009_bib0010","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.cardfail.2020.06.003","article-title":"Transforming ambulatory heart failure care in the coronavirus disease-19 era: initial experience from a heart failure disease management clinic","volume":"26","author":"Umapathi","year":"2020","journal-title":"J Card Fail"},{"key":"10.1016\/j.ahj.2020.12.009_bib0011","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000316038","article-title":"Worsening renal function defined as an absolute increase in serum creatinine is a biased metric for the study of cardio-renal interactions","volume":"116","author":"Testani","year":"2010","journal-title":"Cardiology"},{"key":"10.1016\/j.ahj.2020.12.009_bib0012","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ahj.2020.12.009_bib0013","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2020.12.009_bib0014","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/13506129.2018.1498782","article-title":"Seven factors predict a delayed diagnosis of cardiac amyloidosis","volume":"25","author":"Bishop","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.ahj.2020.12.009_bib0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Thirusha","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.12.009_bib0016","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: analysis of the APOLLO study","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.12.009_bib0017","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.12.009_bib0018","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.12.009_bib0019","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11936-019-0743-2","article-title":"Emerging therapies for transthyretin cardiac amyloidosis","volume":"21","author":"Alexander","year":"2019","journal-title":"Curr Treatment Options Cardiovasc Med"},{"key":"10.1016\/j.ahj.2020.12.009_bib0020","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"(Light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.12.009_bib0021","first-page":"65","article-title":"Efficacy of intravenous furosemide versus a novel, pH-neutral furosemide formulation administered subcutaneously in outpatients with worsening heart failure","volume":"6","author":"Gilotra","year":"2018","journal-title":"JACC"},{"key":"10.1016\/j.ahj.2020.12.009_bib0022","doi-asserted-by":"crossref","DOI":"10.1002\/ehf2.12677","article-title":"Outpatient treatment of worsening heart failure with intravenous and subcutaneous diuretics: a systematic review of the literature","author":"Wierda","year":"2020","journal-title":"ESC Heart Failure"},{"key":"10.1016\/j.ahj.2020.12.009_bib0023","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.amjcard.2019.09.039","article-title":"Meta-analysis comparing torsemide versus furosemide in patients with heart failure","volume":"125","author":"Abraham","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2020.12.009_bib0024","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2147\/CEOR.S207127","article-title":"Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States","volume":"11","author":"Quock","year":"2019","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.ahj.2020.12.009_bib0025","article-title":"National burden of heart failure events in the United States, 2006 to 2014","volume":"11","author":"Jackson Sandra","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.12.009_bib0026","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","author":"Kazi Dhruv","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.12.009_bib0027","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2020.12.009_bib0028","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.jacc.2017.08.010","article-title":"Pulmonary artery pressure-guided management of patients with heart failure and reduced ejection fraction","volume":"70","author":"Givertz","year":"2017","journal-title":"J Am Coll Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320304117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320304117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:06:15Z","timestamp":1757570775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870320304117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":28,"alternative-id":["S0002870320304117"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2020.12.009","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2020.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}